In the year 2004, epithelial ovarian cancer (HOC) is expected to be the 4th leading cancer type among cancer-related deaths in women in the United States. Due to its symptomless development and the lack of accurate animal models, EOC pathogenesis remains among the least understood of all major cancers. Alterations in signaling pathways mediated by p53, p16/Rb and HGF/c-met occur frequently and are reported to be associated with the poor clinical prognosis. However, their specific roles in EOC formation remain uncertain. Recently we have demonstrated that the ovarian surface epithelium (OSE) - selective inactivation of tumor suppressor p53 results in carcinogenesis, and that inactivation of the retinoblastoma (Rb) gene dramatically accelerates this process. In this model, neoplasms closely resemble the aggressive variant of human serous adenocarcinoma. Our preliminary results indicate that, in addition to its role in cell proliferation, apoptosis and genomic instability, the cooperation between defective p53 and Rb pathways predisposes OSE to expression of such advanced cancer traits as increased motility and invasion. These traits remain dormant until Hepatocyte Growth Factor (HGF), produced by accumulating stromal cells, activates c-met signaling. To test this hypothesis, we propose (1) to determine contributions of p53 and p16/Rb towards motility and invasion during epithelial ovarian carcinogenesis, and (2) to evaluate roles of HGF and c-met in EOC invasion and intraperitoneal spreading. These studies should advance our understanding of the EOC pathogenesis by demonstrating new biological mechanisms by which defective p53 and Rb pathways may additionally facilitate the course of neoplastic progression and by establishing the role of HGF/c-met signaling as a permissive event leading to invasion during the OSE carcinogenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA112354-01A1
Application #
6983701
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2005-09-01
Project End
2010-06-30
Budget Start
2005-09-01
Budget End
2006-06-30
Support Year
1
Fiscal Year
2005
Total Cost
$280,845
Indirect Cost
Name
Cornell University
Department
Other Basic Sciences
Type
Schools of Veterinary Medicine
DUNS #
872612445
City
Ithaca
State
NY
Country
United States
Zip Code
14850
Flesken-Nikitin, Andrea; Hwang, Chang-Il; Cheng, Chieh-Yang et al. (2013) Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 495:241-5
Gu, Xiaoling; Vedvyas, Yogindra; Chen, Xiaoyue et al. (2012) Novel strategy for selection of monoclonal antibodies against highly conserved antigens: phage library panning against ephrin-B2 displayed on yeast. PLoS One 7:e30680
Migone, Fernando F; Ren, Yi; Cowan, Robert G et al. (2012) Dominant activation of the hedgehog signaling pathway alters development of the female reproductive tract. Genesis 50:28-40
HogenEsch, Harm; Nikitin, Alexander Yu (2012) Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models. J Control Release 164:183-6
Hwang, Chang-Il; Matoso, Andres; Corney, David C et al. (2011) Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A 108:14240-5
Hwang, Chang-Il; Choi, Jinhyang; Zhou, Zongxiang et al. (2011) MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF. Cell Cycle 10:3834-40
Corney, David C; Hwang, Chang-Il; Matoso, Andres et al. (2010) Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16:1119-28
Cheng, Le; Ramesh, Anirudh V; Flesken-Nikitin, Andrea et al. (2010) Mouse models for cancer stem cell research. Toxicol Pathol 38:62-71
Corney, David C; Nikitin, Alexander Yu (2008) MicroRNA and ovarian cancer. Histol Histopathol 23:1161-9
Corney, David C; Flesken-Nikitin, Andrea; Choi, Jinhyang et al. (2008) Role of p53 and Rb in ovarian cancer. Adv Exp Med Biol 622:99-117

Showing the most recent 10 out of 14 publications